Adherence in children with growth hormone deficiency treated with r-hGH and the easypod™ device
| Autor: | Mariacarolina Salerno, Sandro Loche, P. Garofalo, Giuseppe Citro, Raffaella Perrone, Salvatore Longobardi, Licenziati, M. Maghnie, Marco Cappa, Giuliana M. Cardinale, M. Caruso Nicoletti |
|---|---|
| Přispěvatelé: | Loche, S, Salerno, Mariacarolina, Garofalo, P, Cardinale, G. M, Licenziati, M. R, Citro, G, Caruso Nicoletti, M, Cappa, M, Longobardi, S, Maghnie, M, Perrone, R. |
| Rok vydání: | 2016 |
| Předmět: |
Blood Glucose
Male medicine.medical_specialty Adherence Easypod™ Growth disorders (GD) IGF-1 Endocrinology Diabetes and Metabolism 030209 endocrinology & metabolism Dwarfism 030204 cardiovascular system & hematology Growth hormone deficiency Medication Adherence Poor adherence Growth velocity 03 medical and health sciences Easypod™ 0302 clinical medicine Endocrinology Drug Delivery Systems Internal medicine medicine Humans Prospective Studies Insulin-Like Growth Factor I Prospective cohort study Child Dwarfism Pituitary Growth Disorders business.industry Human Growth Hormone Human growth hormone medicine.disease Diabetes and Metabolism Injection device Growth disorders (GD) Fully automated Pituitary Adherence IGF-1 Observational study Female Original Article Electronics business |
| Zdroj: | Journal of Endocrinological Investigation |
| ISSN: | 1720-8386 |
| Popis: | PURPOSE: Poor adherence to recombinant human growth hormone (r-hGH) therapy is associated with reduced growth velocity in children with growth hormone deficiency (GHD). This twelve-month observational study was to assess adherence in r-hGH patients treated with the easypod™, an electronic, fully automated injection device designed to track the time, date and dose administered. METHODS: Ninety-seven prepubertal patients receiving r-hGH therapy were included in the study from ten Italian clinical sites and 88 completed the study. To avoid possible confounding effects, only GHD patients (79/88; 89.7 % of the overall study population) were considered in the final analysis. The primary endpoint-adherence to treatment-was calculated as the proportion of injections correctly administered during the observational period out of the expected total number of injections. The relevant information, tracked by the easypod™, was collected at months 6 (V1) and 12 (V2) after baseline (V0). At study termination, adherence data were partially available from 16 patients and fully available from 53 patients. As secondary endpoints, serum IGF-1 levels, fasting serum glucose and insulin levels and key anthropometric characteristics (height, waist circumference and BMI) were also determined. RESULTS: The easypod™ data showed that 56.7 % of the patients were considered to be fully (≥92 %) adherent to their treatment throughout the period V0-V2. Treatment improved stature, significantly increased IGF-1 and produced a non-significant increase in blood glucose and insulin levels. CONCLUSIONS: The injection-recording system and other characteristics of easypod™ could enhance the ability of physicians to monitor adherence to r-hGH treatment. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink